Emerging Targets in Diseases with High Unmet Need | Tables and Figures

ORDER NOW

ORDER NOW!

Print
$2,750.00

Single-site or operational unit license
$3,500.00

Country or Global license
Contact David Cunningham,
Account Manager,
781-972-5472
cunningham@
healthtech.com

Length
202 pages

Date published
June 2006

Additional info
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Emerging Targets in Diseases with High Unmet Need: Alzheimer's Disease, Lung Cancer, Dyslipidemia, Type 2 Diabetes, and COPD

By Allan B. Haberman, Ph.D., Haberman Associates, The Biopharmaceutical Consortium

New Page 1

Figure 3.1. The Ras Pathway and Tumor Drug Sensitivity

Figure 4.1. High-Density Lipoprotein and Cholesterol Efflux from the Arterial Wall

Figure 5.1. S6 Kinase 1 and Feedback Regulation of Insulin Signaling

Table 1.1. Major Types of Target Evaluation Technologies

Table 2.1. Selected Emerging Targets in Alzheimer’s Disease

Table 3.1. Types of Lung Cancer

Table 3.2. Selected Emerging Targets in Lung Cancer

Table 4.1. Accepted Modifiable Risk Factors for Coronary Heart Disease

Table 4.2. Selected Emerging Targets in Dyslipidemia

Table 5.1. Major Current Therapies for Type 2 Diabetes

Table 5.2. Selected Emerging Targets in Type 2 Diabetes

Table 6.1. Selected Emerging Targets in COPD

About Insight Pharma Reports

How to Order

Journalist Inquiries

Corporate Librarians and Information Services Inquiries

The Insight Pharma Reports Advisory Board

Contact Insight Pharma Reports

"CHI's Insight
Pharma Reports are
a cost-effective and reliable source
of information about the markets
we serve. The cost
for us to conduct
this kind of business
research on our
own would be
prohibitive. CHI's
Insight Pharma
Reports allow us to
keep on top of
developments in
this rapidly moving
field."

--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences

A division of
Cambridge
Healthtech Institute